CTLA4 and melanoma: To investigate potential immunotherapy responses in SCLC subtypes, we performed SubMap analysis by comparative gene expression profiling between a publicly available cohort of 47 melanoma patients treated with anti-PD-1 and anti-CTLA-4 and the SCLC ferroptosis subtype.